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Abstract Here, we report the identification of a human
orthologue of fibulin-4, along with analysis of its biosynthetic
processing and mRNA expression levels in normal and tumour
tissues. Comparative sequence analysis of fibulin-4 cDNAs
revealed apparent polymorphisms in the signal sequence that
could account for previously reported inefficient secretion in
fibulin-4 transfectants. In vitro translation of fibulin-4 mRNA
revealed the presence of full-length and truncated polypeptides,
the latter apparently generated from an alternative translation
initiation site. Since this polypeptide failed to incorporate into
endoplasmic reticulum membrane preparations, it was concluded
that it lacked a signal sequence and thus could represent an
intracellular form of fibulin-4. Using fluorescence in situ
hybridisation analysis, the human fibulin-4 gene was localised
to chromosome 11q13, this region being syntenic to portions of
mouse chromosomes 7 and 19. Considering the fact that
translocations, amplifications and other rearrangements of the
11q13 region are associated with a variety of human cancers, the
expression of human fibulin-4 was evaluated in a series of colon
tumours. Reverse transcription-polymerase chain reaction anal-
ysis of RNA from paired human colon tumour and adjacent
normal tissue biopsies showed that a significant proportion of
tumours had V2^7-fold increases in the level of fibulin-4 mRNA
expression. Taken together, results reported here suggest that an
intracellular form of fibulin-4 protein may exist and that
dysregulated expression of the fibulin-4 gene is associated with
human colon tumourigenesis. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Members of the ¢bulin gene family are characterised by a
unique C-terminal ¢bulin-type module and several repeated
epidermal growth factor (EGF)-like domains, most of which
possess a consensus motif for calcium binding [1]. Fibulin-1
and -2 proteins exhibit the capacity to self-associate [2,3] and
display a similar, but not entirely overlapping, repertoire of
extracellular matrix (ECM) protein binding partners [2,4^10].
These ECM protein partners include ¢bronectin, nidogen,
laminin, collagen IV and endostatin. In some cases, the bind-
ing sites within ¢bulin-1 and -2 that mediate these various
protein^protein interactions have been discovered [11,12].
Both of these ¢bulins exhibit alternative splicing of RNA
transcripts. Other ¢bulins have been identi¢ed more recently:
S1-5/EFEMP1 (¢bulin-3), MBP1/H411/EFEMP2 (¢bulin-4)
and EVEC/DANCE (¢bulin-5) [13^15]. This subset of the
family (class B) is signi¢cantly smaller than either ¢bulin-1
or -2 (class A) and lacks certain structural/functional domains
at the N-terminus when compared to the original progenitors
of the family [12]. In addition, the terminal location(s) of
¢bulin-3 protein is still ill-de¢ned, with the choice of whether
to remain inside the cell or be secreted perhaps dependent on
alternative RNA splicing and/or selection of di¡erent trans-
lation initiation sites [14].
Fibulin gene family members have been associated with a
variety of biological processes including embryonic develop-
ment and organogenesis, haemostasis and thrombosis, ¢bro-
genesis, tissue homeostasis and remodelling [1]. Fibulins are
thought to serve structural roles within the ECM. In addition,
¢bulins may interact, either directly or indirectly, with recep-
tors at the cell surface, thus providing an avenue for regula-
tion of cell behaviour. Indeed, ¢bulins have been shown to
modulate cell morphology, growth, adhesion and motility
[14,16^19]. Dysregulation of ¢bulin expression/activity may
have pathobiological consequences. For example, up-regula-
tion of ¢bulin-5 mRNA expression has been observed in dis-
eased vasculature, notably in atherosclerotic and balloon-in-
jured blood vessels, this being re£ective of a putative role in
tissue remodelling [15,19]. More speci¢cally, a single non-con-
servative point mutation (Arg345Trp) within one of the EGF-
like domains of ¢bulin-3 has been clearly associated with two
autosomal dominant retinopathies, namely Malattia Leventi-
nese and Doyne honeycomb retinal dystrophy [20].
Fibulins also appear to impact upon the process of tu-
mourigenesis. There is increasing evidence pointing to a tu-
mour suppressive role for ¢bulin-1 [17,18]. Ectopic overex-
pression of ¢bulin-1 in tumour cells has been shown to
delay tumour formation in vivo and suppress anchorage-in-
dependent cell growth, motility and invasion in vitro [17,18].
One current hypothesis is that ¢bulin-1 acts as a negative
regulator of cell motility, one of whose normal functions is
to prevent invasion of tumour cells into surrounding tissues.
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However, a recent study showed elevated levels of ¢bulin-1
protein within the stroma of human ovarian carcinomas in
comparison to normal ovaries [21]. Expression of ¢bulin-3
mRNA is induced during the processes of cell growth arrest
and senescence [13]. This apparently negative growth regula-
tory role for ¢bulin-3 is contradicted by the observation of
up-regulated ¢bulin-3 mRNA levels in transformed cell lines.
In a similar vein, microinjection of in vitro transcribed ¢bulin-
3 mRNA into normal human ¢broblasts stimulated DNA
synthesis of injected cells, as well as some surrounding cells.
In summary, the role of ¢bulins in cancer is still controversial
and further work is needed to fully resolve the above-men-
tioned seemingly ambiguous observations.
Mouse ¢bulin-4, also known as MBP1, was originally iden-
ti¢ed by our research group [14]. Fibulin-4 was found as a
speci¢c protein partner for mutant p53, and displays both
mutant p53-dependent and -independent oncogenic proper-
ties. In addition, ¢bulin-4 provides new insight into the mu-
tant p53 ‘gain of function’ phenotype, which may have sig-
ni¢cant implications for both cancer biology and therapeutic
intervention [22]. One hypothesis whereby ¢bulin-4 interacts
with mutant p53 is that this interaction occurs within the lu-
men of the endoplasmic reticulum as ¢bulin-4 follows the
secretory pathway. Another possibility is that certain isoforms
of ¢bulin-4 (lacking the leading signal sequence) stay within
the cell, these being generated by di¡erential post-transcrip-
tional processing and/or translation initiation. Fibulin-4 and
mutant p53 can synergise in functional terms to promote tu-
mour cell growth and increase rates of neoplastic transforma-
tion. This provides a physiological basis for a relationship,
whether interaction-dependent or not, between these disparate
proteins. It should also be restated that ¢bulin-4 also exhibits
oncogenic properties that are independent of mutant p53, with
this concept being clearly worth further exploration. Indeed, a
recent study from another research group has also provided
evidence of a growth stimulatory role for ¢bulin-4 [23] ; in this
case the hamster version (H411) of ¢bulin-4 was studied.
The following report describes the characterisation, in both
biochemical and genetic terms, of human ¢bulin-4.
2. Materials and methods
2.1. In vitro translation
Mouse and human ¢bulin-4 cDNA was transcribed and translated
in vitro using the TNT coupled reticulocyte lysate system (Promega),
with T7 RNA polymerase being used for transcription. 1 Wg of ¢bulin-
4 cDNA expression vector plasmid was placed in a ¢nal reaction
volume of 50 Wl containing 25 Wl TNT rabbit reticulocyte lysate, 2 Wl
TNT reaction bu¡er, 1 Wl TNT T7 RNA polymerase, 1 Wl 1 mM
amino acid mixture (minus Met), 1 Wl 40 U/Wl RNaseOUT (Gibco
BRL) and 1 WCi 35S-Met (NEN Life Science Products). Co-transla-
tional and initial post-translational processing events were mediated
by inclusion of 3 Wl nuclease-treated canine pancreatic microsomal
membranes (CMM; Promega) to the above reaction mixture. The
positive control mRNAs, the precursors for Saccharomyces cerevisiae
K-factor and Escherichia coli L-lactamase, were used at 0.2 Wg/50 Wl
reaction. Following a 1 h incubation at 30‡C, 10 Wl of each translation
reaction was analysed on a 12% gel by SDS^PAGE. Gels were vac-
uum-dried using a gel dryer, with radioactive emissions detected by
exposure to Kodak BMR ¢lm.
2.2. Proteinase K digestion and deglycosylation
15 Wl of translated product was subjected to digestion with Triti-
rachium album-derived proteinase K (Boehringer Mannheim) in a ¢nal
reaction volume of 20 Wl, which contained 2 Wl reaction bu¡er
(250 mM Tris^HCl pH 7.5, 500 mM NaCl, 15 mM EDTA) plus
one of the following: (a) 3 Wl water, (b) 2 Wl water and 1 Wl 100 mg/
ml proteinase K (having been pre-digested at 37‡C for 30 min), or
(c) 1 Wl proteinase K (pre-digested) and 2 Wl 10% Triton X-100. Di-
gestion was carried out for 1 h on ice. Reactions were terminated by
the addition of 4 Wl 18 mM phenylmethylsulfonyl£uoride, with the
incubations being continued for a further 30 min. Digests were imme-
diately boiled for 3 min following addition of conventional SDS sam-
ple bu¡er. 40 Wl of each digest was analysed by SDS^PAGE as before.
Translated products were examined for evidence of glycosylation
using the N-glycosidase F deglycosylation system (Boehringer Mann-
heim). In more detail, 5 Wl of the translation mixture in 1% Triton
X-100 was denatured at 95‡C for 3 min in an equal volume of the
reduced denaturation bu¡er contained within the above kit. The de-
natured samples were then mixed with equal volumes of reaction
bu¡er (again kit-derived) and incubated overnight in the presence or
absence of N-glycosidase F (42 U/reaction). It should be noted that
Triton X-100 at this concentration allows access of the N-glycosidase
enzyme to membrane-protected translated proteins without adversely
a¡ecting N-glycosidase activity. SDS sample bu¡er was added to each
reaction followed immediately by boiling for 3 min and analysis by
SDS^PAGE as above.
2.3. RNA hybridisation analysis
Human ¢bulin-4 and GAPDH-speci¢c probes were generated from
the above-mentioned testis cDNA library by polymerase chain reac-
tion (PCR) ampli¢cation using the following primers:
Human ¢bulin-4
Forward, 5P-GCCCTGATGGTTACCGCAAGA-3P
Reverse, 5P-AGCCCCCATGGAAGTTGACAC-3P
Human GAPDH
Forward, 5P-CGGAGTCAACGGATTTGGTCGTAT-3P
Reverse, 5P-AGCCTTCTCCATGGTGGTGAAGAC-3P
Hybridisation of PCR-derived probes to Northern blots proceeded as
indicated previously [14]. Quantitation of hybridisation signals was
achieved by electronic autoradiography using an Instant Imager
plus associated analysis software (Packard).
2.4. Fluorescence in situ hybridisation (FISH)
FISH analysis was performed by Genaxis Biotechnology (Mon-
tigny-le-Bretonneux, France) using a full-length human ¢bulin-4
cDNA probe on cytogenetic preparations from a normal human
male. Metaphase chromosomes were prepared according to conven-
tional procedures and normal karyotypes veri¢ed. The probe was
labelled by nick translation with 11-dUTP-biotin (Genaxis Biotech-
nology), with hybridisation occurring overnight in a denaturing moist
chamber. Washes, signal detection and ampli¢cation were performed
according to the standard chromosome in situ hybridisation protocol.
The chromosomes were counter-stained with 4,6-diamidino-2-phenyl-
indole antifade and visualised with an Olympus AX 70 £uorescent
microscope equipped with a PSI Power Gene FISH System analyser.
2.5. RNA isolation and semi-quantitative reverse transcription
(RT)-PCR
Frozen tissue biopsies, i.e. colon tumour and paired normal sam-
ples, were homogenised in RNA NOW solution (Ozyme) using a
Polytron probe. At least 1.0 ml of RNA NOW solution was used
per 100 mg of tissue and total RNA isolation proceeded according
to the manufacturer’s recommendations. RNA yields were quanti¢ed
by spectrophotometry, with RNA integrity being assessed by conven-
tional agarose gel electrophoresis. Single-stranded cDNA was pro-
duced using 1.5 Wg total RNA in combination with the First-Strand
cDNA Synthesis kit (Amersham Pharmacia). The ¢rst-strand reaction
was primed by the NotI-d(T)18 oligonucleotide contained within this
kit. For semi-quantitative RT-PCR analysis of human ¢bulin-4 (prim-
ers shown above) and L-actin (primers indicated below) mRNA, serial
dilutions were made of the above cDNA preparations and PCR am-
pli¢cation performed on these using the primers listed below. PCR
products were analysed by agarose gel electrophoresis and visualised
by ethidium bromide staining.
Human L-actin
Forward, 5P-GTGGGGCGCCCCAGGCACCA-3P
Reverse, 5P-CGGTTGGCCTTGGGGTTCAGGGGGG-3P
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3. Results
3.1. Identi¢cation and characterisation of human ¢bulin-4
cDNA
Human ¢bulin-4 was identi¢ed by a PCR-based approach
from a commercially available testis-derived cDNA library
(GenBank accession AX023967; see Section 5). The open
reading frame (ORF) within the human ¢bulin-4 cDNA was
easily determined by comparison with both mouse and ham-
ster ¢bulin-4 forms (Fig. 1). All three ¢bulin-4 cDNAs contain
a major ORF of 443 amino acids in length, which includes a
putative signal sequence at the N-terminus. This leaves 5P and
3P untranslated terminal regions (UTRs) of 57 and 90 bp,
respectively, for human ¢bulin-4. Considerable conservation,
in terms of primary protein structure, was noted between the
species homologues of ¢bulin-4 (amino acid sequence identi-
ties, mouse versus hamster: 97.1%; human versus hamster:
96.8%; human versus mouse: 95.3%), with the only di¡erence
being single amino acid substitutions. Indeed, all forms exhib-
it the same number of EGF-like repeats (six in all), along with
a short proline-rich region inserted within the ¢rst EGF-like
domain. In addition, a similar pro¢le was seen with respect to
consensus sites for potential post-translational modi¢cations,
such as N-glycosylation and L-hydroxylation. One notable
exception is the presence of a putative O-glycosylation site
(with Ser30 being the a¡ected residue) within the N-terminal
end of both human and hamster ¢bulin-4 proteins, which is
not found in the mouse equivalent (Pro30).
In the past year, several groups have either published
[24,25], or solely deposited into GenBank (AK000980;
AB030655), nucleotide sequences (cDNA only) encoding for
human ¢bulin-4 protein. Using the CLUSTALW (1.8) multi-
ple sequence alignment program [26], the respective nucleotide
and predicted amino acid sequences, as de¢ned by the as-
sumed major ORF, were compared (data not shown). There
were found to be notable sequence di¡erences between the
di¡erent versions of human ¢bulin-4, with the cDNA that
we have obtained appearing to represent the de¢nitive con-
sensus. Apparent single nucleotide polymorphisms (SNPs)
within the ORF portion of the human ¢bulin-4 were as fol-
lows: codon 5 (GCC to ACC), missense mutation (Ala to
Thr); codon 96 (CCC to CTC), missense mutation (Pro to
Leu); codon 191 (GGC to GGT), silent mutation; codon
355 (AGC to AGA), missense mutation (Ser to Arg); codon
356 (GTG to GTA), silent mutation.
It is unclear, as yet, whether the above alterations are au-
thentic or due to sequencing errors within the individual lab-
oratories concerned. The apparent SNPs at codons 96
(AK000980), 355 [26] and 356 [26] have been seen only
once, while those at codons 5 and 191 were observed at the
same time by two independent laboratories ([25] and
AB030655). The described tissue sources of origin for human
¢bulin-4 cDNA isolation, apart from the testis-derived cDNA
library used in this study, are melanoma [25], foetal brain [26]
and 10 week old embryo (AK000980), consisting mainly of
tissue around the head region. Finally, there appears to be
Fig. 1. Amino acid sequence comparison between human, mouse and hamster ¢bulin-4 proteins. Human ¢bulin-4 is the main sequence shown,
numbers starting from the primary initiation codon, with amino acid variations from the mouse and hamster forms indicated above the respec-
tive residues. The six calcium-binding EGF-like domains are numbered sequentially, with the location of the numerals demarcating the start of
these repeats. The ¢bulin-type module begins at amino acid position 326 (Arg), as highlighted by the vertical arrow. The putative N-terminal
signal sequence of human ¢bulin-4 is italicised, with the signal peptidase cleavage site between amino acid positions 27 (Pro) and 28 (Gln)
being marked by a solid triangle. Candidate motifs for post-translational modi¢cations include two N-glycosylation sites (solid boxes) and four
asparagine hydroxylation sites (hatched boxes). Potential O-glycosylation sites in human and hamster ¢bulin-4 at amino acid position 30 (Ser)
are indicated by bold typeface. The putative alternative translation initiation site at amino acid position 69 is shown by the following symbol,
s .
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sequence di¡erences at both the 5P and 3P UTRs of the var-
ious ¢bulin-4 cDNAs, suggestive of alternative splicing events
in these regions (data not shown).
From here on, we will refer to our sequence as human
¢bulin-4, with the other human variants de¢ned when appro-
priate.
3.2. In vitro translation of ¢bulin-4
The calculated molecular weight of both mouse and human
precursor ¢bulin-4 proteins, without taking into consideration
the putative post-translational modi¢cations mentioned
above, is 49.4 kDa. In vitro translation of recombinant mouse
and human ¢bulin-4 produced major polypeptides of 54 kDa
(Fig. 2A, lanes 1 and 2). Mouse and human ¢bulin-4 proteins
are relatively rich in negatively charged amino acids, with
aspartate and glutamic acid residues comprising 12.4% of
the total number of amino acids in both cases. The estimated
isoelectric points are 4.76 and 4.79, respectively. Takano et al.
[27] have suggested that such acidic characteristics may con-
tribute to overestimation of molecular mass by SDS^PAGE.
Translation of ¢bulin-4 also yielded a minor protein prod-
uct of 46 kDa (Fig. 2A, lane 2), suggesting usage of a down-
stream translation initiation site. This phenomenon was much
more prevalent in the case of human, rather than mouse,
¢bulin-4, i.e. with the former reaching nearly 10% of the total
translated protein. While several candidate initiation codons
occur just downstream from the major translation start site,
only one of these had a corresponding termination codon that
would allow production of a polypeptide of this size. Trans-
lation from this AUG leads to a theoretical in-frame product
of 42.0 kDa, encompassing amino acids 69^443 of the major
translated protein. The reduction in relative translation e⁄-
ciency of the minor product observed in the case of mouse
¢bulin-4 may be due to further divergence of the concerned
translation initiation site, by comparison to human ¢bulin-4,
from an optimal consensus sequence for translation initiation
[28]. It will be interesting to see if the alternative ¢bulin-4
polypeptide is produced under physiological conditions, and
whether it has speci¢c functions of its own.
The respective molecular weight of processed mouse and
human ¢bulin-4 proteins, assuming signal peptide cleavage
at predicted sites and lack of post-translational modi¢cation,
are 46.6 and 46.7 kDa. Microsomal membranes, which are
portions of the endoplasmic reticulum, can be used with stan-
dard in vitro translation reactions in order to simulate certain
key co-translational processing and post-translational modi¢-
cation events, such as signal sequence cleavage and core N-
glycosylation [29]. Interestingly, no change was seen with re-
spect to the size of in vitro translated mouse and human
¢bulin-4 protein when the translation reactions were per-
formed in either the presence or absence of CMM (Fig. 2A,
lanes 4 and 5). Under the same conditions, controls for signal
sequence cleavage (L-lactamase) and core glycosylation (K-fac-
tor) showed clear evidence of co-translational and post-trans-
lational processing, respectively (Fig. 2B). Giltay et al. [24]
reported the apparent molecular weight of secreted human
¢bulin-4 protein to be 54 kDa, as determined by SDS^
PAGE under reducing conditions. In keeping with the in vi-
tro translation results presented above, this would suggest
that mature human ¢bulin-4 is post-translationally modi-
¢ed to some extent, most likely by N-glycosylation (see
Fig. 1), such that direct evidence of signal peptide cleavage
is masked.
In addition, Giltay et al. mentioned an inherent di⁄culty in
obtaining secreted recombinant human ¢bulin-4 protein fol-
Fig. 3. Signal peptide cleavage and N-glycosylation of mouse and
human ¢bulin-4. A: Proteinase K digestion of in vitro translated ¢-
bulin-4. Mouse and human ¢bulin-4 proteins, translated in the pres-
ence of CMM, were incubated in either the absence (3) or presence
(+) of proteinase K (Pro K) and Triton X-100 (Tx100). B: Enzy-
matic deglycosylation of in vitro translated ¢bulin-4. Translated ¢-
bulin-4 proteins, following incubation with CMM, were digested
with N-glycosidase F (N-gly F). The control glycoprotein was trans-
ferrin, and was visualised by conventional staining with Coomassie
Blue. +, N-gly F; 3, absence of N-gly F.
Fig. 2. A: In vitro translation of mouse and human ¢bulin-4.
Translation reactions were performed either in the absence (3) or
presence (+) of CMM. Apparent molecular weights of the translated
products were determined by comparison with 14C-labelled protein
size markers. Lanes 1 and 4, mouse ¢bulin-4 cDNA expression vec-
tor; lanes 2 and 5, human ¢bulin-4 cDNA expression vector; lanes
3 and 6, vector alone control. B: Co-translational processing and
post-translational modi¢cation of control mRNAs. Upon exposure
to CMM, the precursor form (17 kDa) of the K-factor is converted
to a 30 kDa protein due to extensive glycosylation. Similarly, pre-L-
lactamase (32 kDa) is reduced in size upon cleavage of a 3 kDa sig-
nal peptide, forming mature L-lactamase. Precursor and processed
species are indicated by Pre and Pro, respectively.
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lowing transfection of an episomal ¢bulin-4 cDNA expression
vector into human kidney cells [24]. The discrepancies noted
above with respect to the predicted amino acid sequence of
human ¢bulin-4 protein may provide an explanation. The
amino acid residue envisaged at codon 5 is either alanine or
threonine depending upon the research group involved. The
human ¢bulin-4 cDNA cloned in this study encodes for an
alanine residue at the amino acid position concerned. It
should also be noted that both the mouse and hamster forms
of ¢bulin-4 code for an alanine residue at the equivalent ami-
no acid position [14,23]. Signal sequence function is deter-
mined, amongst other factors, by the balance between the
central hydrophobic core of the signal peptide and the N-
terminal charge [30]. The presence of a polar residue such as
threonine within the hydrophobic segment may adversely af-
fect the function of the ¢bulin-4 signal sequence, thus leading
to ine⁄cient co-translational processing. Indeed, use of the
SignalP (V2.0) signal sequence prediction server [31,32] indi-
cated that the threonine-containing signal peptide should be
slightly less e¡ective, than the alanine-based version, with re-
spect to being cleaved after insertion into the endoplasmic
reticulum (data not shown). This may explain the low levels
of secreted recombinant ¢bulin-4 protein, when directed from
native signal sequence, mentioned by Giltay et al. [24].
3.3. Signal peptide cleavage and N-glycosylation
Mouse and human ¢bulin-4 proteins, having been trans-
lated in vitro in the presence of CMM, were subjected to
proteolytic digestion by proteinase K (Fig. 3A). In the absence
of a membrane solubilising detergent, such as Triton X-100,
there was no change in the amount of either mouse or human
¢bulin-4 protein after proteinase K digestion. This indicates
that both ¢bulin-4 proteins are translocated in entirety across
the lipid bilayer. While the major ¢bulin-4 proteins (54 kDa)
were una¡ected in this scenario, the minor polypeptide (46
kDa) seen clearly in the case of human ¢bulin-4 was com-
pletely digested by proteinase K even in the absence of deter-
gent. This is in agreement with the concept that this minor
polypeptide does not contain a signal peptide and, thus,
would not undergo co-translational processing. In the pres-
ence of Triton X-100, both the mouse and human ¢bulin-4
major protein products were found to undergo complete di-
gestion. This further indicates that the lipid bilayer of the
microsomal membrane protects against proteinase K-medi-
ated proteolytic digestion of ¢bulin-4 [33].
As indicated in Fig. 1, mouse and human ¢bulin-4 have two
consensus sites for N-glycosylation, with Asn198 and Asn394
being the potentially modi¢ed residues. Taking the molecular
weight of both signal peptides to be approximately 3 kDa, this
being equivalent to that estimated for two standard aspara-
gine (N)-linked carbohydrate side chains, simultaneous signal
sequence cleavage and N-glycosylation might explain the lack
of size di¡erence between ¢bulin-4 proteins translated with/
without microsomal membranes mentioned above. This sce-
nario was tested by subjecting ¢bulin-4, translated in the pres-
ence of microsomal membranes, to digestion with N-glycosi-
dase F (Fig. 3B). This enzyme acts by cleaving N-linked
oligosaccharides from the protein backbone. The electropho-
retic mobility of both mouse and human ¢bulin-4 protein
increased following digestion with N-glycosidase F, with the
apparent molecular weight of the deglycosylated protein cor-
responding to V51 kDa (as opposed to 54 kDa for undi-
gested protein). A control glycoprotein, transferrin, which
has a molecular weight of 65 kDa and also contains two
N-linked glycan chains, showed a similar reduction in size
by 3 kDa upon digestion with N-glycosidase F.
In conclusion, the signal sequences of both mouse and hu-
man ¢bulin-4 are expected to be fully functional with respect
to insertion of translated protein into the lumen of the endo-
plasmic reticulum. In addition, we have con¢rmed here that
¢bulin-4 is N-glycosylated.
Fig. 5. Mapping of the human ¢bulin-4 gene to chromosome 11q13
by FISH. A: Metaphase spread of chromosomes with twin £uores-
cent hybridisation spots indicated by the white arrow, these being
obtained with human ¢bulin-4 cDNA as the probe. B: Close-up
view of metaphase chromosome 11, with ¢bulin-4 hybridisation sig-
nals appearing adjacent to the centromere on the distal arm of the
chromosome.
Fig. 4. Expression of ¢bulin-4 mRNA in human adult tissues. RNA hybridisation analysis of the levels of human ¢bulin-4 mRNA found with-
in two commercially available multiple tissue Northern blots (Clontech). RNA loading was evaluated by hybridisation with a GAPDH-speci¢c
probe. The relative abundance (RA) of ¢bulin-4 mRNA is expressed as a function of the GAPDH mRNA signal.
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3.4. Tissue-speci¢c expression of the human ¢bulin-4 gene
Expression of human ¢bulin-4 mRNA was, as determined
by Northern blot analysis, shown to be di¡erentially regulated
in a tissue-speci¢c manner in the human adult (Fig. 4). For
example, a high level of ¢bulin-4 gene expression was observed
in heart and ovarian tissue, with more moderate expression
levels seen in the spleen, prostate, intestine and colon. Signi¢-
cantly lower expression levels for ¢bulin-4 mRNA were noted
in all other tissues examined, with notably weak signals in the
brain, liver and skeletal muscle. The expression pattern for the
¢bulin-4 gene observed in certain adult tissues, as detailed in
the left hand panel of Fig. 4, agrees with ¢bulin-4 mRNA
expression results previously shown by Giltay et al. [24]. Fur-
thermore, we also observed the same two mRNA isoforms of
1.5 and 1.8 kb in size, these being most likely obtained by
alternative RNA splicing. Interestingly, the ratio in terms of
expression between the major (1.8 kb) and minor (1.5 kb)
mRNA forms appeared to be the same independent of tissue
type. While the expression pro¢le of ¢bulin-4 mRNA between
mouse and human adult tissues are quite similar, there are
some notable di¡erences, e.g. low level of ¢bulin-4 gene ex-
pression in the mouse heart compared to a markedly high
level in humans, and vice versa with respect to the expression
of ¢bulin-4 mRNA in lung tissue [14].
3.5. Physical mapping of the human ¢bulin-4 gene
The chromosomal localisation of the human ¢bulin-4 gene
was determined by FISH using full-length human ¢bulin-4
cDNA as a probe. Of 30 normal human metaphase cells ex-
amined, 25 displayed a speci¢c hybridisation signal with twin
spots at 11q13 (Fig. 5). Secondary hybridisation signals at
other chromosomal regions were not observed. Utilising
PCR-based ampli¢cation of a portion of the 3P UTR of the
human ¢bulin-4 gene from monochromosomal and radiation
cell hybrids as well as previously mapped genomic clones, a
recent study mapped the human ¢bulin-4 gene to the same
region [25]. 11q13 is notably gene-rich and contains an exten-
sive number of disease-related loci, including those involving
bone disorders, retinopathies and cancer [34]. This human
chromosomal band displays regions of homology with por-
tions of mouse chromosomes 7 and 19 [34], with the latter
chromosome being the most likely location for the mouse
¢bulin-4 gene when taking into consideration the genetic map-
ping data presented elsewhere [25].
3.6. Aberrant expression of ¢bulin-4 mRNA in human colon
tumours
Levels of ¢bulin-4 mRNA were assessed by semi-quantita-
tive RT-PCR in a small panel of paired normal/tumour hu-
man colon tissue biopsies (n = 9). Expression of the ¢bulin-4
gene in normal colon tissue varied considerably in di¡erent
patients (Fig. 6), preventing direct comparison of gene expres-
sion levels in colon tumour tissue between individuals. Anal-
ysis of colon tumour tissue from each patient showed evidence
of aberrant ¢bulin-4 mRNA expression in seven out of the
nine patients. Five of these patients displayed up-regulation of
¢bulin-4 mRNA in the tumour relative to normal tissue, with
fold di¡erences ranging from 2.0 to 6.8. Down-regulation of
¢bulin-4 mRNA was observed in two patients, with fold dif-
ferences being 2.0 and 2.3 in these cases.
4. Discussion
An accumulating body of evidence suggests a growth stim-
ulatory role for ¢bulin-4 [14,23]. As indicated in a previous
study from our group, mouse ¢bulin-4 promoted cell growth
when overexpressed in a human lung tumour cell line [14]. In
addition, hamster ¢bulin-4 stimulated the growth rate of sta-
bly transfected macrophages [23]. This potential role for ¢bu-
lin-4 in mediating proliferative responses may be shared by
other ¢bulin family members, with ¢bulin-3 being a notable
example [13]. These growth regulatory actions are thought to
primarily occur through an autocrine mechanism of action,
with secreted ¢bulin-4 protein acting either directly or indi-
rectly on, as yet unidenti¢ed, cell surface receptors. The ob-
servation of a downstream translation initiation codon in ¢-
bulin-4, which as seen above produces a mature protein minus
signal sequence, may implicate a cytoplasmic role for this
protein. While the physiological relevance of such an intra-
cellular form of ¢bulin-4 is not readily apparent, we have
shown before that N-terminally deleted mouse ¢bulin-4 re-
tains some oncogenic activity, albeit not as markedly as that
observed with full-length protein [14]. This study supports the
hypothesis that an intracellular form of ¢bulin-4 exists, and
Fig. 6. RT-PCR analysis of ¢bulin-4 mRNA expression in human colon tumours. The main details of the approach used for semi-quantitative
RT-PCR analysis are detailed in Section 2. Paired normal (N) and tumour (T) tissue biopsies from di¡erent patients are indicated by numbers
1^9. Positive DNA controls for human ¢bulin-4 and L-actin are indicated by C. The human testis cDNA library was also used as a secondary
control for PCR ampli¢cation from complex cDNA populations. The level of ¢bulin-4 mRNA was expressed as a function of L-actin gene ex-
pression, with this data being used to calculate the fold di¡erences between normal and tissue samples from the same patient. A fold di¡erence
(3 or +) of greater than or equal to 2.0 was deemed to be within the limit of sensitivity in terms of quantitation.
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that mutant p53/¢bulin-4 protein^protein interactions may
occur in either of two ways: (a) mutant p53 enters the lumen
of the endoplasmic reticulum and physically interacts with
¢bulin-4 as it passes along the secretory pathway [14], and/
or (b) an intracellular form of ¢bulin-4 physically interacts
with mutant p53 within the cytoplasm.
The human ¢bulin-4 gene has now been mapped by two
independent research groups, each using di¡erent approaches,
to chromosome 11q13. Based on this chromosomal localisa-
tion and analogy to the macular dystrophy-causing mutation
in ¢bulin-3 [20], this marks ¢bulin-4 a prime candidate for the
following inherited retinopathies which have been linked to
11q13: neovascular in£ammatory vitreoretinopathy, familial
exudative vitreoretinopathy, Bardet-Biedl syndrome 1 and
congenital ¢brosis of the extraocular muscles. Several heredi-
tary diseases involving dysregulated bone homeostasis have
been mapped to this region also, such as osteoporosis-pseu-
doglioma syndrome, high bone mass and osteopetrosis. Indi-
viduals with some of these bone disorders often exhibit pro-
gressive blindness and deafness, along with other
complications. Taking into consideration the potential role
of other ¢bulins in the development of skeletal structures
[35], it may prove to be informative to look more closely at
the involvement of ¢bulin-4 in the above, as well as other,
bone disorders.
Other inherited disorders mapped to this region, which have
not as yet been connected to a disease-causing gene or genes,
include insulin-dependent diabetes mellitus 4, spinocerebellar
ataxia 5, non-syndromic hearing loss, Meckel syndrome type 2
and acromegaly/gigantism. In speci¢c relation to carcinogen-
esis, the distal portion of 11q13 undergoes ampli¢cation in a
number of common human tumours, including oesophageal,
head and neck, bladder, lung and breast cancer [36,37]. Gene
ampli¢cation at 11q13 is complex, with multiple amplicons
having been reported which occur primarily at the distal por-
tion of 11q13. Oncogenes resident at 11q13 include CCND1,
EMS1, FGF3, FGF4 and FOSL1, with ampli¢cation events
generally involving di¡erent combinations of these genes. In
addition, 11q13 is a common target for chromosomal trans-
locations and other rearrangements during tumourigenesis.
Previous evidence suggests that the human ¢bulin-4 gene is
located at the proximal portion of 11q13 close to the centro-
mere [25], which may obviate against this candidate oncogene
being part of the major 11q13 cancer-related amplicon.
The up-regulation of ¢bulin-4 mRNA expression noted in
human colon tumours relative to normal tissue is consistent
with the putative oncogenic role for this gene. While it is
possible that more discrete ampli¢cations comprising the ¢bu-
lin-4 gene may occur, the increased expression of the ¢bulin-4
gene is probably due to either enhanced translation or in-
creased mRNA stability. Interestingly, expression of the ¢bu-
lin-1 gene has recently been shown to be regulated through
selective translation [38]. The down-regulation of ¢bulin-4
mRNA levels seen in two of the colon tumours is perhaps
re£ective of non-¢bulin-4-speci¢c chromosomal rearrange-
ments. The lack of consistent trend with respect to ¢bulin-4
mRNA expression in the colon tumour samples versus normal
colon specimens may be re£ective of the multi-factorial basis
of this disease. Although this pilot study was relatively limited
in terms of sample size, this work provides the basis for much
larger clinical studies assessing the role of ¢bulin-4 in colon
cancer, along with other tumour types.
5. Supplementary material
5.1. Cloning of human ¢bulin-4
The nucleotide sequence of the predicted ORF from mouse
¢bulin-4 cDNA [14] was used to search for homologous hu-
man expressed sequence tags (ESTs) present within the Gen-
Bank database. The ESTs used for this inquiry were taken
from the human dbEST library. Over 60 human ESTs dis-
played a high degree of sequence similarity (s 85% sequence
identity) with mouse ¢bulin-4 cDNA [14]. These ESTs
spanned various sections of mouse ¢bulin-4, with the majority
being localised to the 3P end of the ORF. Using one of the
most 5P situated human ESTs from this 3P subset (GenBank
accession: AA055998), primers were designed so as to allow
overlapping PCR-based ampli¢cation of the 5P and 3P ends of
human ¢bulin-4 DNA. A human testis cDNA library was
chosen as the starting material for PCR ampli¢cation. This
choice was in£uenced by the previous observation in the
mouse of a high expression level of mouse ¢bulin-4 mRNA
within this particular tissue type [14]. Thus, the commercially
available SuperScript human testis cDNA library (Gibco
BRL) was used as the substrate for PCR-based ampli¢cation
of ¢bulin-4. Internal ¢bulin-4 and library vector-speci¢c prim-
er pairs were used as follows:
5P ¢bulin-4 cDNA fragment
Forward, 5P-AGCTATTTAGGTGACACTATAG-3P
(vector-speci¢c: SP6).
Reverse, 5P-CTCCGCTCCGAGGTGATGGTC-3P
(internal ¢bulin-4).
3P ¢bulin-4 cDNA fragment
Forward, 5P-TGTAGCTACTCCAGCTACCTC-3P
(internal ¢bulin-4).
Reverse, 5P-TAATACGACTCACTATAGGGAGA-3P
(vector-speci¢c: T7).
Use of the above primer sets allowed PCR-mediated ampli-
¢cation of overlapping 5P and 3P fragments of human ¢bulin-4
cDNA, with the largest of these being approximately 1.20 and
0.75 kb in size, respectively. Multiple independent PCR prod-
ucts were placed into the pCR II cloning vector (Invitrogen),
with insert-containing plasmid clones being sequenced at a
number of times. Subsequently, a consensus sequence for
full-length human ¢bulin-4 cDNA was derived taking into
account the 326 bp overlapping sequence. The longest 5P
and 3P cDNA fragments were joined together using the re-
striction enzymes EcoRI, NcoI and NotI and the intermediary
recipient plasmid, pBC-SK+/3 (Stratagene). The entire hu-
man ¢bulin-4 cDNA was then cloned into the pcDNA3 mam-
malian gene expression vector (Invitrogen) using the restric-
tion enzymes HindIII and NotI. Finally, the reconstituted
human ¢bulin-4 cDNA was con¢rmed several times by
DNA sequencing. The total nucleotide sequence for human
¢bulin-4 cDNA was 1479 bp.
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